These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27292568)

  • 1. The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation.
    Porcù E; Persano L; Ronca R; Mitola S; Bortolozzi R; Romagnoli R; Oliva P; Basso G; Viola G
    Sci Rep; 2016 Jun; 6():27886. PubMed ID: 27292568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular disrupting activity of combretastatin analogues.
    Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
    Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound.
    Park K; Lee HE; Lee SH; Lee D; Lee T; Lee YM
    Oncotarget; 2017 Jan; 8(5):7801-7813. PubMed ID: 27999195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis.
    Porcù E; Viola G; Bortolozzi R; Persano L; Mitola S; Ronca R; Presta M; Romagnoli R; Baraldi PG; Basso G
    Angiogenesis; 2013 Jul; 16(3):647-62. PubMed ID: 23456551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
    Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
    Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
    Chen MC; Lee CF; Huang WH; Chou TC
    Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
    Nagaraju GP; Zhu S; Ko JE; Ashritha N; Kandimalla R; Snyder JP; Shoji M; El-Rayes BF
    Cancer Lett; 2015 Feb; 357(2):557-65. PubMed ID: 25497868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
    Oh SH; Woo JK; Jin Q; Kang HJ; Jeong JW; Kim KW; Hong WK; Lee HY
    Int J Cancer; 2008 Jan; 122(1):5-14. PubMed ID: 17764071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AECHL-1, a novel triterpenoid, targets tumor neo-vasculature and impairs the endothelial cell cytoskeleton.
    Dasgupta A; Sawant MA; Lavhale MS; Krishnapati LS; Ghaskadbi S; Sitasawad SL
    Angiogenesis; 2015 Jul; 18(3):283-99. PubMed ID: 25952529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
    Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
    Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation.
    Li MH; Miao ZH; Tan WF; Yue JM; Zhang C; Lin LP; Zhang XW; Ding J
    Clin Cancer Res; 2004 Dec; 10(24):8266-74. PubMed ID: 15623602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation.
    Mahal K; Biersack B; Caysa H; Schobert R; Mueller T
    Invest New Drugs; 2015 Jun; 33(3):541-54. PubMed ID: 25678082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation.
    Lin MT; Yen ML; Lin CY; Kuo ML
    Mol Pharmacol; 2003 Nov; 64(5):1029-36. PubMed ID: 14573751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
    Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
    Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA-1H, a novel oxazole bearing analogue of combretastatin A-4, disrupts the tumor vasculatures and inhibits the tumor growth via inhibiting tubulin polymerization.
    Han F; Wang P; Zhang W; Li J; Zhang Q; Qi X; Liu M
    Biomed Pharmacother; 2016 May; 80():151-161. PubMed ID: 27133052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis.
    DeNiro M; Alsmadi O; Al-Mohanna F
    Exp Eye Res; 2009 Nov; 89(5):700-17. PubMed ID: 19580810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indenoisoquinoline derivatives as topoisomerase I inhibitors that suppress angiogenesis by affecting the HIF signaling pathway.
    Xu X; Liu F; Zhang S; Jia J; Li Z; Guo X; Yang Y; Sun H; You Q
    Biomed Pharmacother; 2013 Oct; 67(8):715-22. PubMed ID: 23932721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferulic acid augments angiogenesis via VEGF, PDGF and HIF-1 alpha.
    Lin CM; Chiu JH; Wu IH; Wang BW; Pan CM; Chen YH
    J Nutr Biochem; 2010 Jul; 21(7):627-33. PubMed ID: 19443196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The saponin monomer of dwarf lilyturf tuber, DT-13, inhibits angiogenesis under hypoxia and normoxia via multi-targeting activity.
    Zhao R; Sun L; Lin S; Bai X; Yu B; Yuan S; Zhang L
    Oncol Rep; 2013 Apr; 29(4):1379-86. PubMed ID: 23404207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.